ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1273

Effect of Anti-Cyclic Citrullinated Protein Antibodies and Rheumatoid Factor on Bone Erosions in Early Rheumatoid Arthritis Patients Using HR-pQCT: A Cross-Sectional Study

JIANG YUE1, James F Griffith2, Lin Shi3, Defeng Wang2, Jiayun Shen4, Priscilla Wong5, Edmund LI5, Martin Li6, Tena K. Li6, Tracy Y. Zhu7, Ling qin8 and Lai-Shan TAM9, 1The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, HONG KONG, Hong Kong, 2The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Imaging and Interventional Radiology, HONGKONG, Hong Kong, 3Department of Medicine & Therapeutics, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong, 4Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China, 5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 6Department Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China, 7Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China, 8Department of Orthopedics & Traumatology, hongkong, Hong Kong, 9Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ACPA, HR-pQCT, Imaging and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Concomitant presence of anti-cyclic citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) is associated with higher erosive disease burden in patients with established rheumatoid arthritis (RA). Even before the clinical onset of arthritis, ACPAs are associated with bone loss. Whether RF also influences bone damage in patients with RA is less well defined. In this study, we aim to determine whether there is an effect of ACPA and RF on the number and volume of bone erosions in early rheumatoid arthritis (ERA) patients.

Methods:

In this cross-sectional study, the second metacarpophalangeal joint (MCP2) in 96 patients with ERA (onset of disease within 2 years) were assessed using high-resolution peripheral quantitative CT (HR-pQCT). Data on demographic (age, sex) and disease-specific parameters including DAS 28, ESR, CRP, ACPA and RF levels were recorded. Erosions were visualized in 73 patients and the number and volume of the erosions were documented. Relationship between erosions, demographic and disease-specific data was evaluated by two multiple linear regression models.

Results:

Amongst the 96 ERA patients, 72.9% were female. The mean age was 53.1±13.8 years, disease duration was 8.0±5.6 months and DAS 28 was 5.0 ±0.9. Out of the 96 patients, 75 were both RF and ACPA positive (ACPA+/RF+), 5 were RF positive only (ACPA-/RF+), 9 were ACPA positive only (ACPA+/RF-) and 7 were double negative (ACPA-/RF-). Erosion volume was higher in the ACPA+/RF+ group compared with the non- ACPA+/RF+ (ACPA-/RF+ or ACPA+/RF- or ACPA-/RF-) group (3.99±3.16 mm3 vs 2.50±1.24 mm3, p=0.023). When all patients were subdivided according to RF and ACPA titer, erosion volume was significantly larger in the RF positive (>16 U) group than the RF negative (<16 U) group (4.28±3.42 mm3 vs 2.66±1.34 mm3, p=0.019). Similarly, erosion volume was also significantly larger in the ACPA>100U group compared to the ACPA<100U group (2.94±3.19 mm3 vs 1.64±1.34 mm3, p=0.010). Erosion volume was also increased in female patients (Beta=0.315, p=0.012). On the other hand, erosion number was associated with increasing age (Beta=0.359, p=0.000), ESR (Beta=0.320, p=0.001) and longer disease duration (Beta=0.251, p=0.014) in the univariate analysis. Using multiple linear regression model, independent explanatory variables associated with erosion volume included RF>16U (p=0.018) and female gender (p=0.011); while erosion number was associated with a longer disease duration (p=0.021), older age (p=0.000) and elevated ESR (p=0.007).

Conclusion:

In RA patients with recent onset of disease, the number of erosion appears to depend on disease activity, while the presence of RF may play a predominant role in the structural deterioration in terms of erosion volume. .


Disclosure: J. YUE, None; J. F. Griffith, None; L. Shi, None; D. Wang, None; J. Shen, None; P. Wong, None; E. LI, None; M. Li, None; T. K. Li, None; T. Y. Zhu, None; L. qin, None; L. S. TAM, None.

To cite this abstract in AMA style:

YUE J, Griffith JF, Shi L, Wang D, Shen J, Wong P, LI E, Li M, Li TK, Zhu TY, qin L, TAM LS. Effect of Anti-Cyclic Citrullinated Protein Antibodies and Rheumatoid Factor on Bone Erosions in Early Rheumatoid Arthritis Patients Using HR-pQCT: A Cross-Sectional Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/effect-of-anti-cyclic-citrullinated-protein-antibodies-and-rheumatoid-factor-on-bone-erosions-in-early-rheumatoid-arthritis-patients-using-hr-pqct-a-cross-sectional-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-anti-cyclic-citrullinated-protein-antibodies-and-rheumatoid-factor-on-bone-erosions-in-early-rheumatoid-arthritis-patients-using-hr-pqct-a-cross-sectional-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology